Christiansen, Sara NysomHorskjær Rasmussen, SimonPons, MarionMichelsen, BrigitteGlintborg, BenteGudbjornsson, BjornGrondal, GerdurVencovsky, JiriLoft, Anne GitteRotar, ZigaPirkmajer, Katja PerdanNissen, Michael J.Baranová, JanaMacfarlane, Gary J.Jones, Gareth T.Iannone, FlorenzoCaporali, RobertoLaas, KarinVorobjov, SigridGiuseppe, Daniela DiOlofsson, TorProvan, Sella AarrestadFagerli, Karen MindeCastrejon, IsabelOtero-Varela, Luciavan de Sande, Marleenvan der Horst-Bruinsma, IreneNordström, DanKuusalo, LauraBernardes, MiguelHetland, Merete LundØstergaard, MikkelMidtbøll Ørnbjerg, Lykke2024-05-022024-05-022024-04Christiansen, S N, Horskjær Rasmussen, S, Pons, M, Michelsen, B, Glintborg, B, Gudbjornsson, B, Grondal, G, Vencovsky, J, Loft, A G, Rotar, Z, Pirkmajer, K P, Nissen, M J, Baranová, J, Macfarlane, G J, Jones, G T, Iannone, F, Caporali, R, Laas, K, Vorobjov, S, Giuseppe, D D, Olofsson, T, Provan, S A, Fagerli, K M, Castrejon, I, Otero-Varela, L, van de Sande, M, van der Horst-Bruinsma, I, Nordström, D, Kuusalo, L, Bernardes, M, Hetland, M L, Østergaard, M & Midtbøll Ørnbjerg, L 2024, 'Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice', Seminars in arthritis and rheumatism, vol. 65, 152388. https://doi.org/10.1016/j.semarthrit.2024.1523880049-0172ORCID: /0000-0003-2322-3314/work/159078448https://hdl.handle.net/2164/23395On behalf of the EuroSpA Scientific Committee, the authors acknowledge Novartis Pharma AG for supporting the EuroSpA collaboration.102416396engBiologic therapyClinical study in epidemiologyCohort studyRheumatic diseasesSpondyloarthritisRS Pharmacy and materia medicaRheumatologyAnesthesiology and Pain MedicineRSJournal article10.1016/j.semarthrit.2024.152388http://www.scopus.com/inward/record.url?scp=85184021202&partnerID=8YFLogxK65